TrialsgrambetaRCTs are beautiful

IRIS

2003

International Randomized Study of Interferon and STI571

In 1,106 patients with newly diagnosed chronic-phase CML, imatinib improved cytogenetic response and progression-free survival compared with interferon-α + cytarabine.

Result

18-month cytogenetic response
Absolute difference
61.7 points

The absolute difference is derived from the event rates.

Also reported: 10-yr OS 83.3%; 10-yr complete cytogenetic response in 82.8%.

Original publication
Subtopic
Chronic myeloid leukaemia
Design
Open-label RCT
Relevance
Practice-defining: a trial the field needs to know.
Source
O'Brien SG, et al. N Engl J Med. 2003;348(11):994-1004; Hochhaus A, et al. N Engl J Med. 2017;376(10):917-927.doi 10.1056/NEJMoa022457

Discussion & critique

Transformed CML from a uniformly fatal disease to one with near-normal life expectancy. Foundation for the entire BCR-ABL TKI class.